<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180217038766N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-03-04</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>"Impact of Motivational Interview on Self-Efficacy", "Impact of Motivational Interview on Beliefs Medicines " "Impact of Motivational Interview on Medication Adherence"</public_title>
      <acronym></acronym>
      <scientific_title>The Impact of Motivational Interview on Self-Efficacy, Beliefs Medicines and Medication Adherence among Adolescents with Asthma</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-02-14</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>52</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/29733</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Single, Purpose: Prevention, Randomization description: The research method is block random assignment in two groups of intervention and control. For this purpose blocks of size 4 will be used. To create a random sequence, the randomizer.org website will be used to hide the random allocation, and the numbered dark envelopes will be used, in which the group name will be specified in the random sequence generated. Then, according to the order of entering samples, the sample for the first sample of the envelope number one is opened and the group will be identified until the end, Blinding description: Bilingual blindness was conducted in participants and researchers in a way that the participants received the questionnaire after hearing the study objectives and the willingness of the company to study and sign the written consent, without the participants being aware that In the intervention group, or in the control group. The researcher also does not know that the participant is in the control group or the intervention, since after completing the questionnaire, the researcher opens the packet based on the random block and then realizes that the sample is in the control group or Intervention If the sample is in the control group, the researcher determines the post-test time for the sample and if the sample is in the intervention group, the researcher talks about setting the time for the intervention to be performed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Adolescents with Asthma.</hc_freetext>
      <i_freetext>Intervention group: There is only one intervention group. In the intervention group, motivational interviewing takes place in four sessions of 40 to 60 minutes, individually per week based on the protocol described (for each motivational interview session). Session 1: Patient Assessment, Second Session: Interview with Patient in Connection with Environmental and External Barriers to Drug Abuse, Third Session: Interview with Patient in Connection with Individual and Internal Barriers to Drug Abuse, Session Four: Promoting Self-Efficacy Levels The client.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
A portion of the information, such as information on the main outcome or the like, can be shared.

When:
"Starting the access period 12 months after printing results"

To whom:
Researchers working in academia and academia

Conditions:
Only the results of the study are to be used and, except for this case, there is no right in the analysis or other matters.

Where to obtain:
atefeh barikani .by email barikani2000@gmail.com

How to obtain:
Whoever wants the study information should contact Atefeh Barikani by email. And if he accepts the terms from his / her side, the respondent will be informed as soon as possible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>atefeh barikani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran East Nusrat Street. School of Nursing and Midwifery, Tehran University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3361648783</zip>
        <telephone>+98 26 4422 1284</telephone>
        <email>barikani2000@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>reza negarandeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran East Nusrat Street.Schoole of Nursing and Midwifery, Tehran University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3361648783</zip>
        <telephone>+98 21 6105 4581</telephone>
        <email>negarandeh@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The criteria for entering the study include: ages 10 to 18 years, asthma diagnosis in the past year by the physician, the occurrence of moderate and severe persistent asthma, daily use of asthma prevention by corticosteroids, non-use of the drug for problems other than illness Asthma is the ability to speak Persian and desire to communicate with scholars.</inclusion_criteria>
      <agemin>10 years</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unwillingness to participate in the study, hospitalization during the study period, incidents and unrelated stressful experiences during the study, absence from the motivational interview in two consecutive sessions, attendance in other educational and counseling programs during the study Are also considered as exclusion criteria.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J45</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Asthma</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: There is only one intervention group. In the intervention group, motivational interviewing takes place in four sessions of 40 to 60 minutes, individually per week based on the protocol described (for each motivational interview session). Session 1: Patient Assessment, Second Session: Interview with Patient in Connection with Environmental and External Barriers to Drug Abuse, Third Session: Interview with Patient in Connection with Individual and Internal Barriers to Drug Abuse, Session Four: Promoting Self-Efficacy Levels The client</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Drug Compliance (MARS's 10-item questionnaire) was conducted to measure drug compliance, the grading rate was never = 5, rarely = 4, sometimes = 3, most often = 2, always = 1. The scores obtained from this The questionnaire is divided into 10, and thus the range of scores to be obtained in a questionnaire is from 1 to 5. A score of more than 4.5 indicates good drug compliance and a score of less than 4.5 indicates poor drug compliance.). Timepoint: Before intervention and 1 month after the last intervention session. Method of measurement: questionnaire Medication Adherence (MARS).</prim_outcome>
      <prim_outcome>Belief in the questionnaire was a questionnaire consisting of two dimensions of the necessity of drug use and concerns about drug issues. The method of scoring based on Likert scale was totally opposite = 1, opposed = 2 , No matter = 3 I agree = 4 I totally agree = 5. Out of the 11 items, the BMQ 5 questionnaire is followed by concerns about drug issues and 6 afterwards on the need for drug use. The next scores for drug issues concern The sum of these is divided into 5, and the 6th grade points of the next need for drug use are combined and divided into six. The scores that can be obtained from the two dimensions mentioned above can be summarized. Dentistry varies between 1 and 5. Higher score = 5 in the dimension of concerns Concerns about drug issues The BMQ questionnaire indicates more concern about long-term use of the drug and a lower score of 1 indicates a lower concern regarding the long-term use of Medication. But in the case of the need for drug use, a higher score of 5 indicates a greater belief in the necessity of taking the drug for health and a lower score of 1 indicates a lower belief in the necessity of taking the drug to provide health. Timepoint: Before intervention and 1 month after the last intervention session. Method of measurement: questionnaire Beliefs Medicines (BMQ).</prim_outcome>
      <prim_outcome>Self-efficacy (CASES 14-item questionnaire for measuring self-efficacy in adolescents), this questionnaire consists of two dimensions of prevention of asthmatic attacks (Gove1-8) and management of asthmatic attacks (Clause 9-14). The scoring method is not at all safe. = 1, I'm pretty sure = 2, I'm fairly sure = 3, I'm pretty sure = 4, I'm pretty sure = 5. Of the 14 items in the CASES 8 questionnaire, the item is dedicated to preventing asthma attacks and 6 items for management of asthma attacks. The scoring criteria available in the prevention of asthma attacks range from 40-40% and in the management of asthmatic attacks is 6-30. A score of more than 40 in the prevention of asthma attacks indicates better prevention than H Asthma mortality and score less than 8 indicate a weakness in the prevention of asthma attacks and a greater score of 30 in the management of asthma attacks suggests better management of asthmatic attacks and a score of less than 6 indicates a weakness in the management of asthma attacks.). Timepoint: Before intervention and 1 month after the last intervention session. Method of measurement: questionnaire Self-efficacy of childhood with asthma (CASES).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-02-04</approval_date>
        <contact_name>Ethics Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Ghods. Keshavarz Blvd, Tehran Town Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
